alert icon Coronavirus
Now scheduling COVID-19 vaccines for ages 12+, boosters and third doses
Schedule your appointment
COVID-19 vaccine FAQs

Going to a Cleveland Clinic location?
New visitation guidelines
Masks required for patients and visitors (even if you're vaccinated)

Jiong Shi, MD, PhD

Jiong Shi, MD, PhD
  • No ratings
  • 0 Patient Satisfaction Ratings
  • 0 Patient Comments
Title Director, Clinical Trials Program
Department Cleveland Clinic Lou Ruvo Center for Brain Health
Primary Location Lou Ruvo Center for Brain Health - Las Vegas
Type of Doctor Adults Only
Languages Chinese, English
Surgeon No
Lou Ruvo Center for Brain Health - Las Vegas
Primary Location

Lou Ruvo Center for Brain Health - Las Vegas

Specialties & Treatments

Treatment & Services

  • Alzheimer's
  • Shunt
View all 2 Treatment & Services +

Specialty in Diseases & Conditions

  • Alzheimer's
  • Alzheimer's and Dementia
  • Dementia
  • Dementia with Lewy Bodies
  • Frontotemporal Dementia
  • Hydrocephalus
  • Lewy Body Dementia
View all 7 Specialties +


Is Cleveland Clinic Nevada Part of Your Insurance?

For questions about accepted insurance plans for our Nevada locations and specific plan products including Medicare, please contact your insurance carrier directly.

View All Plans

About Jiong Shi, MD, PhD

Dr. Jiong Shi is a board certified neurologist specializing in dementia and other cognitive disorders. He completed his residency and fellowship at University Hospitals of Cleveland and earned a Ph.D. in pharmacodynamics at University of Florida. He sees patients with an array of cognitive disorders from Alzheimer’s disease to Lewy body dementia to frontotemporal dementia and normal pressure hydrocephalus. Dr. Shi focuses his research on finding novel biomarkers and therapeutic agents for Alzheimer’s disease and has published more than 70 peer-reviewed papers. Prior to joining Cleveland Clinic Lou Ruvo Center for Brain Health in May 2020, he was with Barrow Neurological Institute in Phoenix for 16 years.

Dr. Shi directs the Lou Ruvo Center for Brain Health’s clinical research team that is working on early detection, potential new treatments and prevention strategies for Alzheimer’s disease, Lewy body dementia, frontotemporal dementia and other dementias; Parkinson’s and Huntington’s diseases and other movement disorders; and multiple sclerosis. Having conducted more than 80 trials since opening in 2009, the Lou Ruvo Center for Brain Health is one of the largest and most active clinical research facilities for memory disorders in the country.

Dr. Shi is a member of multiple medical societies as well as a Fellow of the American Academy of Neurology (FAAN). He has dedicated considerable attention to education and continues teaching medical students, residents and fellows.

Education & Professional Highlights

Education & Professional Highlights


Education & Fellowships

Residency - University Hospitals Case Medical Center
Cleveland, OH USA

Internship - University Hospitals of Cleveland Health System
Department of Medicine
Cleveland, OH USA

Graduate School - University of Florida Health Science Center
Gainesville, FL USA

Medical Education - Shanghai Medical University Faculty of Medicine

Additional Training

  • Board Certification:

    2006 - Current Diplomat of the American Board of Psychiatry and Neurology


    July 1987- July 1993

    MD, School of Medicine, Shanghai Medical University, Shanghai, China

    January 1994- August 1997   

    PhD, Department of Pharmacodynamics, University of Florida, Gainesville, Florida

    June 2000- June 2001

    Internship, Department of Medicine, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, Ohio

    July 2001- June 2004

    Residency, Department of Neurology, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, Ohio 

Professional Highlights

  • Research Projects:

    1)    National Institute on Aging (P30 AG019610): Arizona Alzheimer's Disease Core Center, Program director: E. M. Reiman.
    Clinical core: (10%, co-investigator, September 2006- June, 2019)
    2)    Arizona Alzheimer's Research Consortium and Arizona Department of Health Services: Effects of aging on brain pituitary adenylate cyclase activating polypeptide, pathology and cognition. (PI, Grant# 455003032421, 2017-2018)
    3)    Flinn Foundation, Novel Biomarkers in Alzheimer’s disease (PI, Grant# 2190, 2018.11-2020.10)

    Clinical Research:

    1)    Principal Investigator: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BIIB037 in Subjects with Early Symptomatic Alzheimer's Disease (AD) (Protocol Number:  BIIB037, ENGAGE) Biogen Idec (2017-2019)
    2)    A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study). Eli Lilly and Company (2015-2017)
    3)    Principal Investigator: A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH900931) in Subjects with Amnestic Mild Cognitive Impairment due to Alzheimer's Disease (prodromal AD). (Protocol Number:  MK8931-019, APECS) Merck (2015-2017)
    4)    Principal Investigator: Phase II, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study of Lu AE58054 in Patients with Mild Moderate Alzheimer's Disease Treated with Donepezil (Protocol Number:  Lundbeck 148621, STARBEAM) Lundbeck (2015-2017)
    5)    Principal Investigator: Avanir Pharmaceuticals, Inc. Investigator Initiated Study: A Prospective, Open-label Study to Assess the Safety and Efficacy of Nuedexta (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients with Alzheimer’s Disease (2013-2015)
    6)    Principal Investigator: Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients with Alzheimer's Disease (H8A-MC-LZAX). Eli Lilly and Company (2014-2015)
    7)    Principal Investigator: Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients with Alzheimer's Disease (H8A-MC-LZAO). Eli Lilly and Company (2012-2015)
    8)    Principal Investigator: Effect of LY2062430, an Anti-Amyloid Beta Monoclonal Antibody, on the Progression of Alzheimer’s Disease as Compared with Placebo (H8A-MC-LZAM). Eli Lilly and Company (2010-2013)
    9) Principal Investigator: A Phase 3, 12-week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Tolerability of 3 Fixed Doses of Brexpiprazole (OPC-34712) in the Treatment of Subjects with Agitiation Associted with Dementia of the Alzheimer's Type (Protocol Number:  Otsuka 331-12-283) Otsuka / INC Research (2014-2015)
    10) Principal Investigator: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease. Baxter (2012-2013)
    11) Principal Investigator: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Investigate Safety and Tolerability of RO5186582 in Individuals with Down Syndrome. Roche (2011-2013)
    12) Principal Investigator: A principal open-label study to compare the brain uptake of [18F]flutemetamol with brain amyloid levels post mortem. GE Healthcare Ltd. and its Affiliates. (2011- 2012)
    13) Principal Investigator: A Principal Open-label Study to Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects with Amnestic Mild Cognitive Impairment Who Will Convert to Probable Alzheimer's Disease. GE Healthcare Ltd. and its Affiliates. (2010- 2013)
    14) Principal Investigator: Tysabri® Global Observation Program in Safety (TYGRIS). Biogen Idec (2007-2015)
    15) Principal Investigator: JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri (STRATIFY-2). Biogen Idec (2010-2014)
    16) Principal Investigator: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis (ADVANCE). Biogen Idec (2009-2011)
    17) Principal Investigator: A Multinational, Multicenter, Open-label, Single-assignment Extension of the MS-LAQ-302 (BRAVO) Study, to Evaluate the Long-term Safety, Tolerability and Effect on Disease Course of Daily Oral Laquinimod 0.6 mg in Subjects With Relapsing Multiple Sclerosis. Teva Pharmaceutical Industries (2010-2014)
    18) Principal Investigator: A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With RRMS to Assess the Efficacy, Safety and Tolerability of Laquinimod Over Placebo in a Double-blind Design and a Reference Arm of Interferon β-1a (Avonex®) in a Rater-blinded Design. Teva Pharmaceutical Industries (2008-2012)
    19) Principal Investigator: Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials (PREMIERE). EMD Serono (2011-2014)
    20) Principal Investigator: Double-blind, Placebo-controlled, Randomized, Parallel-group Phase II Study in Subjects With Relapsing Forms of Multiple Sclerosis (MS) to Evaluate the Safety, Tolerability, and Effects of CDP 323. UCB Pharma (2008-2010)
    21) Principal Investigator: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of PRX-03140 as Monotherapy in Subjects With Alzheimer's Disease. Epix Pharmaceuticals, Inc. (2008-2010)
    22) Principal Investigator: A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy and to Determine the Pharmacokinetics of Two Doses of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients  with Amyotrophic Lateral Sclerosis and Multiple Sclerosis. Avanir Pharmaceuticals (2008-2010)
    23) Principal Investigator: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 26-Week Trial To Evaluate The Efficacy And Safety Of Dimebon In Patients With Moderate-To-Severe Alzheimer's Disease. Pfizer (2008-2010)
    24) Principal Investigator: Development of Peripheral Blood and Urine Diagnostics and Biomarkers for Alzheimer's Disease ("Alzheimer's Diagnostic Study"). Arizona Biomedical Research Commission (ABRC)-Eli Lilly & Company. (2008)
    25) Principal Investigator: APOE polymorphism and the development of cognitive impairment in MS patients. National MS Society (NMSS). (2006-2007)
    26) Principal Investigator: A Randomized, Double-Blind, Placebo-Controlled, Dose-Titration Study to Assess the Safety, Tolerability, and Efficacy of C105 in Persons with Multiple Sclerosis with Cognitive Impairment. Cognition Pharmaceuticals LLC (2007-2008)
    27) Co-investigator (PI: Reyes): An Open-Label Extension Study of Combination Therapy with Dimebon and Donepezil in Patients with Alzheimer's Disease. Medivation, Inc. 2008.
    28) Co-investigator (PI: Reyes) A 12-Week, Multicenter, Open-Label Study to Evaluate the Effectiveness and Safety of Donepezil Hydrochloride (Aricept®) in Hispanic Patients with Mild to Moderate Alzheimer's Disease. Eisai, Inc. & Pfizer, Inc. 2005-06
    29) Co-investigator (PI: Reyes) A Prospective, 26-Week, Open-label, Multi-center, Single-arm Pilot Study to Evaluate the Safety and Tolerability of Exelon® Capsule with add on Memantine HCl in patients with probable Alzheimer's Disease (MMSE 10-20 )2006-07. Novartis Pharmaceuticals Corp.
    30) Co-investigator (PI: Vollmer), A 24-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose Finding, Safety, Tolerability, and Efficacy Study of the Human Anti-IL-12 Antibody ABT-874 in Subjects With Multiple Sclerosis With a 24-Week Double-Blind, Active Extension Phase. Abbott Laboratories 2004-05
    31) Co-investigator (PI: Vollmer), Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR (10 mg B.I.D.) in Subjects with Multiple Sclerosis. Acorda Therapeutics, Inc. 2004-05
    32) Co-investigator (PI: Vollmer), International, randomized, multicenter, phase IIIb study in patients with relapsing-remitting multiple sclerosis comparing over a treatment period of 104 weeks: Double-blinded safety, tolerability, and efficacy of Betaseron®/Betaferon® 250 micrograms (8 MIU) and Betaseron®/Betaferon® 500 micrograms (16 MIU), both given subcutaneously every other day; and Rater-blinded safety, tolerability, and efficacy of Betaseron®/Betaferon® subcutaneously every other day with Copaxone® 20 mg subcutaneously once daily. Berlex 2003-06
    33) Co-investigator (PI: Vollmer), A Phase II/III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab (MabThera®/Rituxan®) in Adults with Primary Progressive Multiple Sclerosis. Genentech, Inc. 2004-05
    34) Co-investigator (PI: Vollmer), A Phase II, Proof-of-Concept, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab (MabThera®/Rituxan®) in Adults with Relapsing-Remitting Multiple Sclerosis. Genentech, Inc. 2004-05
    35) Co-investigator (PI: Vollmer), A Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Efficacy and Safety of Atorvastatin in Patients with Clinically Isolated Syndrome and High Risk of Conversion to Multiple Sclerosis. NIAID/ITN 2004-05
    36) Co-investigator (PI: Vollmer), A Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of Interferon Beta-1a and Glatiramer Acetate to Either Agent Alone in Patients with Relapsing Remitting Multiple Sclerosis (CombiRx-Phase III). NIH/NINDS 2004-05
    37) Co-investigator (PI: Vollmer), A Phase 2 Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study of Subcutaneous Daclizumab® in Patients with Active, Relapsing Forms of Multiple Sclerosis. PDL BioPharma, Inc. 2005
    38) Co-investigator (PI: Vollmer), Phase IV, multicenter, open label, randomized study of Rebif 44 mcg administered three times per week by subcutaneous injection compared with Copaxone® 20 mg administered daily by subcutaneous injection in the treatment of relapsing remitting multiple sclerosis. Serono/Pfizer 2004
    39) Co-investigator (PI: Vollmer), A Multi-Center, Randomized, Single-Blind, Parallel Group Study to Compare the Efficacy, Tolerability and Safety of Copaxone® to that of High Dose Interferon (Betaseron® or Rebif®) in the Treatment of Relapsing Multiple Sclerosis Patients. Teva Neuroscience 2004
    40) Co-investigator (PI: Vollmer), A Multi-Centered, Randomized, Two-Arm, Open Label Study to Evaluate the Safety, Tolerability and Efficacy of Induction Treatment with Mitoxantrone (Novantrone®) Preceding Treatment with Glatiramer Acetate (Copaxone®) versus Chronic Treatment with Glatiramer Acetate Alone in Relapsing Forms of Multiple Sclerosis. Teva Neuroscience 2003-05
    41) Co-investigator (PI: Vollmer), A Multi-Centered, Randomized, Double-Blind, Placebo Controlled Study Assessing the Add-On Effect of Oral Steroids in Relapsing Remitting Multiple Sclerosis Subjects Treated with Glatiramer Acetate (GA). Teva Neuroscience 2004-05.


    1.)  Shi J and Simpkins JW. 17-beta Estradiol modulation of glucose transporter 1 (GLUT1) expression in blood-brain barrier.  American Journal of Physiology: Endocrinology and Metabolism, 272 (6): E1016-E1022, 1997.
    2.)  Shi J, Zhang YQ and Simpkins JW. Effects of 17–beta estradiol on glucose transporter 1 expression and endothelial cell survival following focal ischemia in the rats.  Experimental Brain Research, 117: 200-206, 1997.
    3.)  Shi J, Xiang Y and Simpkins JW. Hypoglycemia enhances the expression of mRNA encoding beta-amyloid precursor protein in rat primary cortical astroglial cells.  Brain Research, 772: 247-251, 1997.
    4.)  Zhang YQ, Shi J, Rajakumar G, Day AL and Simpkins JW. Effects of gender and estradiol treatment on focal brain ischemia.  Brain Research, 784: 321-324, 1998.
    5.)  Simpkins JW, Rabbani O, Shi J, Panickar KS, Green PS, Day AL. A system for the brain-enhanced delivery of estradiol: an assessment of it's potential for the treatment of Alzheimer's disease and stroke. Pharmazie. 1998 Aug;53(8):505-11. Review. PubMed PMID: 9741059.
    6.)  Shi J, Panickar KS, Yang SH, Rabbani O, Day AL, Simpkins JW. Estrogen attenuates over-expression of mRNA that encodes beta-amyloid precursor protein in an animal model of focal ischemia.  Brain Research, 810 (1-2): 87-92, 1998.
    7.)  Shi J, Perry G, Aliev G, Smith MA, Ashe KH, Friedland RP. Serum amyloid P is not present in amyloid-beta deposits of a transgenic animal model.  NeuroReport, 10: 3229-32, 1999.
    8.)  Yang SH, Shi J, Day AL, Simpkins JW. Estradiol exerts neuroprotective effects when administered after ischemic insult. Stroke, 31 (3): 745-9, 2000. (Editorial comment was published in the same issue. Robinson S.E., 749-50).
    9.)  Shi J, Yang SH, Stubley L, Day AL, Simpkins JW. Hypoperfusion induces over-expression of beta-amyloid precursor protein mRNA in a focal ischemic rodent model.  Brain Research, 853: 1-4, 2000.
    10.) Aliev G, Shi J, Perry G, Friedland RP, Lamanna JC. Decreased constitutive nitric oxide synthase, but increased inducible nitric oxide synthase and endothelin-1 immunoreactivity in aortic endothelial cells of Donryu rats on cholesterol-enriched diet.  The Anatomical Record, 206 (1): 16-25, 2000.
    11.) Friedland RP, Shi J, Lamanna JC, Smith MA, Perry G. Prospects for noninvasive imaging of brain amyloid beta in Alzheimer's disease. Annals of the New York Academy of Sciences, 903: 123-8, 2000.
    12.) Shi J, Perry G, Smith MA, Friedland RP. Vascular abnormalities: the insidious pathogenesis of Alzheimer's disease. Neurobiology of Aging, 21(2): 357-61, 2000.
    13.) Aliev G, Seyidov D, Neal ML, Shi J, Vigan T, Hernandez A, Folco G, Soas AH, Zimina TV, Smith MA, Perry G, Lamanna JC, Friedland RP. The effect of agonists and antagonists on the morphology of non-transformed human smooth muscle cell in vitro. Journal of Submicroscopy, Cytology and Pathology, 33(1-2): 141-9, 2001.
    14.) Shi J, Bui JD, Yang SH, He Z, Lucas TH, Buckley DL, Blackband SJ, King MA, Day AL, Simpkins JW. Estrogens decrease reperfusion-associated cortical ischemic damage: an MRI analysis in a transient focal ischemia model. Stroke, 32 (4): 987-92, 2001.
    15.) Aliev G, Smith MA, Seyidova D, Neal ML, Shi J, Loizidou M, Turmaine M, Friedland RP, Taylor I, Burnstock G, Perry G, Lamanna JC. Increased expression of NOS and ET-1 immunoreactivity in human colorectal metastatic liver tumours is associated with selective depression of constitutive NOS immunoreactivity in vessel endothelium. Journal of Submicroscopy, Cytology and Pathology, 34(1): 37-50, 2002.
    16.) Shi J, Perry G, Berridge MS, Aliev G, Siedlak SL, Smith MA, LaManna JC, and Friedland RP. Labeling of cerebral amyloid beta deposits in vivo using intranasal basic fibroblast growth factor and serum amyloid P component in mice. Journal of Nuclear Medicine, 43(8): 1044-51, 2002. (Comment on this paper was published in the same issue: Blass J.P., Potential for a specific neuroradiologic diagnosis of Alzheimer’s disease: 1052-3.)
    17.) Aliev G, Seyidova D, Neal ML, Shi J, Lamb BT, Siedlak SL, Vinters HV, Head E, Perry G, Lamanna JC, Friedland RP, Cotman CW. Atherosclerotic lesions and mitochondria DNA deletions in brain microvessels as a central target for the development of human AD and AD-like pathology in aged transgenic mice. Ann N Y Acad Sci. 2002 Nov;977:45-64. doi: 10.1111/j.1749-6632.2002.tb04798.x. PubMed PMID: 12480733.
    18.) Selkirk S and Shi J. Relapsing remitting tumefactive multiple sclerosis. Mult Scler. 11 (6): 731-734, 2005.
    19.) Sparks DL, Friedland RP, Petanceska S, Schreurs BG, Shi J, Perry G, Smith MA, Sharma A, Derosa S, Ziolkowski C, Stankovic G. Trace copper levels in the drinking water, but not zinc or aluminum influence CNS Alzheimer-like pathology. J Nutr Health Aging. 10 (4): 247-54, 2006.
    20.) Shi J., Zhao C, Vollmer TL, Tyry TM and Kuniyoshi SM. APOE ε4 allele is associated with cognitive impairment in patients with multiple sclerosis. Neurology, 70: 185-190. 2008.
    21.) Shi J. Bateman RJ. Letter to Editor: Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology. 69: 1063-1065, 2007.
    22.) Zhao CB, Coons SW, Cui M, Shi FD, Vollmer TL, Ma CY, Kuniyoshi SM and Shi J. A new EAE model of brain demyelination induced by intracerebroventricular pertussis toxin. Biochem Biophys Res Commun. 370(1): 16-21, 2008. Epub 2008 Mar 11.
    23.) Tu JL, Zhao CB, Vollmer T, Coons S, Lin HJ, Marsh S, Treiman DM, and Shi J. APOE 4 polymorphism results in early cognitive deficits in an EAE model. Biochem Biophys Res Commun. 384(4):466-70, 2009.
    24.) Caselli RJ, Dueck AC, Osborne D, Sabbagh MN, Connor DJ, Ahern GL, Baxter LC, Rapcsak SZ, Shi J, Woodruss BK, Locke DEC, Hoffman Snyder C, Alexander GE, Rademakers R, Reiman EM. Longitudinal modeling of age-related memory decline and the APOE ε4 effect. N Engl J Med. 361 (3): 255-63, 2009.
    25.) Yin JX, Tu JL, Lin HJ, Liu RL, Zhao CB, Coons SW, Kuniyoshi S, Shi J. Centrally administered pertussis toxin inhibits microglia migration to the spinal cord and prevents dissemination of disease in an EAE mouse model. PLoS One. 2010 Aug 25; 5(8):e12400.
    26.) Shi J and Seltzer B. Galantamine: an update. Neurodegenerative Disease Management. 2011 1(3), 227–234.
    27.) Shi J., Tu JL, Gale SD, Baxter L, Vollmer TL, Campagnolo, DI, Tyry TM, Zhuang Y and Kuniyoshi, SM.  APOE ε4 is associated with exacerbation of cognitive decline in patients with multiple sclerosis. Cogn Behav Neurol. 2011 Sep; 24(3): 128-33
    28.) Yin JX, Turner GH, Lin HJ, Coons SW, Shi J. Deficits in Spatial Learning and Memory is Associated with Hippocampal Volume Loss in Aged Apolipoprotein E4 Mice. J Alzheimers Dis. 2011 Jan 1; 27(1):89-98.
    29.) Maalouf M, Ringman JM, Shi J. An update on the diagnosis and management of dementing conditions. Rev Neurol Dis. 2011; 8(3-4):e68-87.
    30.) Tang Z, Yin JX, Han P, Gan Y, Coons SW, Wang C, Maalouf M, Shi J. Pertussis toxin attenuates experimental autoimmune encephalomyelitis by upregulating neuronal vascular endothelial growth factor. Neuroreport. 2013 Jun 19;24(9):469-75.
    31.) Li L, Yin J, Li Y, Tian W, Qiao B, Tang Z, Shi J. Anaplastic astrocytoma masquerading as hemorrhagic stroke. J Clin Neurosci. 2013 Nov;20(11):1612-4.
    32.) Shi J, Han P, Kuniyoshi SM. Cognitive Impairment in Neurological Diseases: Lessons from Apolipoprotein E. J Alzheimers Dis. 2014; 38(1):1-9.
    33.) Tang Z, Wang C, Shi J. A solitary hemangioblastoma located on the trochlear nerve. J Clin Neurosci. 2014 Feb;21(2):333-5.
    34.) Tang Z, Gan Y, Liu Q, Yin JX, Liu Q, Shi J, Shi FD. CX3CR1 deficiency suppresses activation and neurotoxicity of microglia/macrophage in experimental ischemic stroke. J Neuroinflammation. 2014 Feb 3;11(1):26.
    35.) Yin JX, Tang Z, Gan Y, Li, L, Shi F, Coons SW, Shi J. Pertussis toxin modulates microglia and T cell profile to protect experimental autoimmune encephalomyelitis.  Neuropharmacology. 2014 Jan 29;81C:1-5.
    36.) Yin J, Turner GH, Coons SW,  Maalouf M,  Reiman EM, Shi J. Association of amyloid burden, brain atrophy and memory deficits in aged Apolipoprotein ε4 Mice. Current Alzheimer Research 2014 Mar;11(3):283-90.
    37.) Shi, J, Baxter, LC, Kuniyoshi, S. Pathological and imaging correlates of cognitive deficits in multiple sclerosis: changing the paradigm of diagnosis and prognosis. Cogn Behav Neurol. 2014 Mar;27(1):1-7.
    38.) Han P, Liang W, Baxter LC, Yin J, Tang Z, Beach TG, Caselli RJ, Reiman EM, Shi J. Pituitary Adenylate Cyclase Activating Polypeptide is Reduced in Alzheimer’s Disease. Neurology 2014 May 13;82(19):1724-8.
    39.) Han P, Tang Z, Yin J, Maalouf M, Beach TG, Reiman EM, Shi J. Pituitary adenylate cyclase-activating polypeptide protects against β-amyloid toxicity. Neurobiol Aging. 2014 Sep;35(9):2064-71.
    40.) Han P, Caselli RJ, Baxter L, Serrano G, Yin J, Beach TG, Reiman EM, Shi J. Association of Pituitary Adenylate Cyclase-Activating Polypeptide With Cognitive Decline in Mild Cognitive Impairment Due to Alzheimer Disease. JAMA Neurol. 2015 Mar;72(3):333-9.
    41.) Curtis C, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, Beach TG, Duara R, Fleisher AS, Frey KA, Walker Z, Hunjan A, Holmes C, Escovar YM, Vera CX, Agronin ME, Ross J, Bozoki A, Akinola M, Shi J, Vandenberghe R, Ikonomovic MD, Sherwin PF, Grachev ID, Farrar G, Smith AP, Buckley CJ, McLain R, Salloway S. Phase 3 Trial of Flutemetamol Labeled With Radioactive Fluorine 18 Imaging and Neuritic Plaque Density. JAMA Neurol. 2015 Mar;72(3):287-94.
    42.) Han P, Trinidad BJ, Shi J. Hypocalcemia-Induced Seizure: Demystifying the Calcium Paradox. ASN Neuro. 2015 Mar 24;7(2).
    43.) Beach TG, Adler CH, Sue LI, Serrano G, Shill HA, Walker DG, Lue L, Roher AE, Dugger BN, Maarouf C, Birdsill AC, Intorcia A, Saxon-Labelle M, Pullen J, Scroggins A, Filon J, Scott S, Hoffman B, Garcia A, Caviness JN, Hentz JG, Driver-Dunckley E, Jacobson SA, Davis KJ, Belden CM, Long KE, Malek-Ahmadi M, Powell JJ, Gale LD, Nicholson LR, Caselli RJ, Woodruff BK, Rapscak SZ, Ahern GL, Shi J, Burke AD, Reiman EM, Sabbagh MN. Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program. Neuropathology. 2015 Aug;35(4):354-89. doi: 10.1111/neup.12189. Epub 2015 Jan 26.
    44.) Yin J, Han P, Tang Z, Liu Q, Shi J. Sirtuin 3 mediates neuroprotection of ketones against ischemic stroke. J Cereb Blood Flow Metab. 2015 Nov;35(11):1783-9. doi: 10.1038/jcbfm.2015.123. Epub 2015 Jun 10.
    45.) Tang Z, Li S, Han P, Yin J, Gan Y, Liu Q, Wang J, Wang C, Li Y, Shi J. Pertussis toxin reduces calcium influx to protect ischemic stroke in a middle cerebral artery occlusion model. J Neurochem. 2015 Dec;135(5):998-1006. doi: 10.1111/jnc.13359. Epub 2015 Oct 8.
    46.) Yin JX, Maalouf M, Han P, Zhao M, Gao M, Dharshaun T, Ryan C, Whitelegge J, Wu J, Eisenberg D, Reiman EM, Schweizer FE, Shi J. Ketones block amyloid entry and improve cognition in an Alzheimer's model. Neurobiol Aging. 2016 Mar;39:25-37. doi: 10.1016/j.neurobiolaging.2015.11.018. Epub 2015 Dec 7.
    47.) Han P, Shi J. A theoretical analysis of the synergy of amyloid and tau in Alzheimer's disease. J Alzheimers Dis. 2016 Apr 19;52(4):1461-70. doi: 10.3233/JAD-151206.
    48.) Zhang X, Zhang F, Huang D, Wu L, Ma L, Liu H, Zhao Y, Yu S, Shi J. Contribution of Gray and White Matter Abnormalities to Cognitive Impairment in Multiple Sclerosis. Int J Mol Sci. 2016 Dec 27;18(1). pii: E46. doi: 10.3390/ijms18010046.
    49.) Han P, Serrano G, Beach TG, Caselli RJ, Yin J, Zhuang N, Shi J. A Quantitative Analysis of Brain Soluble Tau and the Tau Secretion Factor. J Neuropathol Exp Neurol. 2017 Jan 9. pii: nlw105. doi: 10.1093/jnen/nlw105. [Epub ahead of print]
    50.) Mehta D, Jackson R, Paul G, Shi J, Sabbagh M. Why do trials for Alzheimer's disease drugs keep failing? A discontinued drug perspective for 2010-2015. Expert Opin Investig Drugs. 2017 Jun;26(6):735-739. doi: 10.1080/13543784.2017.1323868
    51.) Han P, Nielsen M, Song M, Yin J, Permenter MR, Vogt JA, Engle JR, Dugger BN, Beach TG, Barnes CA, Shi J. The Impact of Aging on Brain Pituitary Adenylate Cyclase Activating Polypeptide, Pathology and Cognition in Mice and Rhesus Macaques. Front Aging Neurosci. 2017 Jun 12;9:180. doi: 10.3389/fnagi.2017.00180. eCollection 2017.
    52.) Sabbagh MN, Lue LF, Fayard D, Shi J. Increasing Precision of Clinical Diagnosis of Alzheimer's Disease Using a Combined Algorithm Incorporating Clinical and Novel Biomarker Data. Neurol Ther. 2017 Jul;6(Suppl 1):83-95. doi: 10.1007/s40120-017-0069-5. Epub 2017 Jul 21. Review.
    53.) Sun GZ, He YC, Ma XK, Li ST, Chen DJ, Gao M, Qiu SF, Yin JX, Shi J, Wu J. Hippocampal synaptic and neural network deficits in young mice carrying the human APOE4 gene. CNS Neurosci Ther. 2017 Aug 7. doi: 10.1111/cns.12720. [Epub ahead of print]
    54.) Salloway S, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, Beach TG, Duara R, Fleisher AS, Frey KA, Walker Z, Hunjan A, Escovar YM, Agronin ME, Ross J, Bozoki A, Akinola M, Shi J, Vandenberghe R, Ikonomovic MD, Sherwin PF, Farrar G, Smith APL, Buckley CJ, Thal DR, Zanette M, Curtis C. Performance of [18F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease. Alzheimers Dement (Amst). 2017 Jul 1;9:25-34. doi: 10.1016/j.dadm.2017.06.001. eCollection 2017.
    55.) Lieberman A, Deep A, Shi J, Dhall R, Shafer S, Moguel-Cobos G, Dhillon R, Frames CW, McCauley M. Downward finger displacement distinguishes Parkinson disease dementia from Alzheimer disease. Int J Neurosci. 2018 Feb;128(2):151-154. doi: 10.1080/00207454.2017.1379518. Epub 2017 Oct 2.
    56.) Yin J, Han P, Song M, Nielsen M, Beach TG, Serrano GE, Liang WS, Caselli RJ, Shi J. Amyloid-β Increases Tau by Mediating Sirtuin 3 in Alzheimer's Disease. Mol Neurobiol. 2018 Nov;55(11):8592-8601.
    57.) Wolk DA, Sadowsky C, Safirstein B, Rinne JO, Duara R, Perry R, Agronin M, Gamez J, Shi J, Ivanoiu A, Minthon L, Walker Z, Hasselbalch S, Holmes C, Sabbagh M, Albert M, Fleisher A, Loughlin P, Triau E, Frey K, Høgh P, Bozoki A, Bullock R, Salmon E, Farrar G, Buckley CJ, Zanette M, Sherwin PF, Cherubini A, Inglis F. Use of Flutemetamol F 18-Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment. JAMA Neurol. 2018 May 14. doi: 10.1001/jamaneurol.2018.0894. [Epub ahead of print]
    58.) Sabbagh MN, Shi J, Lee M, Arnold L, Al-Hasan Y, Heim J, McGeer P. Salivary beta amyloid protein levels are detectable and differentiate patients with Alzheimer's disease dementia from normal controls: preliminary findings. BMC Neurol. 2018 Sep 26;18(1):155. doi: 10.1186/s12883-018-1160-y.
    59.) Yin J, Li S, Nielsen M, Carcione T, Liang WS, Shi J. Sirtuin 3 attenuates amyloid-β induced neuronal hypometabolism. Aging (Albany NY). 2018 Oct 23;10(10):2874-2883. doi: 10.18632/aging.101592.
    60.) Song M, Lieberman A, Fife T, Nielsen M, Hayden S, Sabbagh M, Shi J. A prospective study on gait dominant normal pressure hydrocephalus. Acta Neurol Scand. 2019 Apr;139(4):389-394. doi: 10.1111/ane.13064. Epub 2019 Feb 19.
    61.) Li S, Yin J, Nielsen M, Beach TG, Guo L, Shi J. Sirtuin 3 Mediates Tau Deacetylation. J Alzheimers Dis. 2019;69(2):355-362. doi: 10.3233/JAD-190014.
    62.) Brunet HE, Miller JB, Shi J, Chung B, Munter BT, Sabbagh MN. Does informant-based reporting of cognitive symptoms predict amyloid positivity on positron emission tomography? Alzheimers Dement (Amst). 2019 Jun 6;11:424-429. doi: 10.1016/j.dadm.2019.04.004. eCollection 2019 Dec.
    63.) Cao R, Li S, Yin J, Guo L, Shi J. Sirtuin 3 promotes microglia migration by upregulating CX3CR1. Cell Adh Migr. 2019 Dec;13(1):229-235. doi: 10.1080/19336918.2019.1629224.
    64.) Yin J, Nielsen M, Li S, Shi J. Ketones improves Apolipoprotein E4-related memory deficiency via sirtuin 3. Aging (Albany NY). 2019 Jul 7;11. doi:10.18632/aging. 102070.  [Epub ahead of print]
    65.) Malek-Ahmadi M, Beach TG, Zamrini E, Adler CH, Sabbagh MN, Shill HA, Jacobson SA, Belden CM, Caselli RJ, Woodruff BK, Rapscak SZ, Ahern GL, Shi J, Caviness JN, Driver-Dunckley E, Mehta SH, Shprecher DR, Spann BM, Tariot P, Davis KJ, Long KE, Nicholson LR, Intorcia A, Glass MJ, Walker JE, Callan M, Curry J, Cutler B, Oliver J, Arce R, Walker DG, Lue LF, Serrano GE, Sue LI, Chen K, Reiman EM. Faster cognitive decline in dementia due to Alzheimer disease with clinically undiagnosed Lewy body disease. PLoS One. 2019 Jun 25;14(6):e0217566. doi: 10.1371/journal.pone.0217566. eCollection 2019.
    66.) Yin J, Nielsen M, Carcione T, Li S, Shi J. Apolipoprotein E regulates mitochondrial function through the PGC-1α-sirtuin 3 pathway. Aging (Albany NY). 2019 Dec 6;11. doi: 10.18632/aging.102516. [Epub ahead of print]
    67.) Yin J, Reiman EM, Beach TG, Serrano GE, Sabbagh MN, Nielsen M, Caselli RJ, Shi J Effect of ApoE isoforms on mitochondria in Alzheimer's disease. Neurology. 2020 May 26:10.1212/WNL.0000000000009582. doi: 10.1212/WNL.0000000000009582. Online ahead of print.PMID: 32457210

    Books and Chapters:

    1.  Perry, G., Nunomura, A., Friedlich, A.L., Boswell, M.V., Brazdil, L.,Jones, P.K., Rottkamp, C.A., Zhu, X., Raina, A.K., Hirai, K., Friedland, R.P.,Shi, J., Aliev, G., Cash, A., Russell, R.L., Wataya, T., Shimohama, S., Atwood,C.S., Smith, M.A., Factors controlling oxidative damage in Alzheimer disease:metals and mitochondria. “Free Radicals in Chemistry, Biology andMedicine", edited by T. Yoshikawa, S. Toyokuni, Y. Yamamoto, and Y. Naito,OICA International: London, ISBN: 1 903063 04 3, August 2000.
    2.  Simpkins, J.W., Green, P.S., Gridley, K.E., Shi,J., Monck, E.K., Neuroprotective effects of estrogens. “Biology of Menopause”, edited by Bellino, F.L., Proceedings of the International Symposium on Biologyof Menopause, Serono Symposia USA: Massachusetts,  ISBN:0-387-98987-0, 20


  • Psychiatry and Neurology - Neurology

Awards & Honors

  • 2015- 2017  Best Doctors in America
  • 2015- 2016  Top Neurologist in Phoenix, AZ, the International Association of HealthCare Professionals
  • 2010- 2011  America’s top physician, Consumers’ Research Council of America


  • Society Membership:

    2003- Current       Fellow, American Academy of Neurology

    2011- Current       Member, Behavioral Neurology Section, American Academy of Neurology

    2012- Current       Member, Geriatric Neurology Section, American Academy of Neurology

Research & Publications

Research & Publications

See publications for Jiong Shi, MD, PhD.

(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)

Industry Relationships

Industry Relationships

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 9/18/2021, Dr. Shi has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Consulting and/or Speaking. Dr. Shi receives fees of $5,000 or more per year as a paid consultant, speaker or member of an advisory committee for the following companies:

  • Roche (Hoffman-La Roche, Ltd.)

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.

Related Videos Featuring Jiong Shi, MD, PhD

Related Videos Featuring Jiong Shi, MD, PhD

Back to Top